Mariëlle P K J Engelen1, Renate Jonker2, John J Thaden2, Gabriella A M Ten Have2, Moon Sun Jeon2, Srinivasan Dasarathy3, Nicolaas E P Deutz2. 1. Center for Translational Research in Aging & Longevity, Dept of Health and Kinesiology, Texas A&M University, College Station, TX, USA. Electronic address: mpkj.engelen@ctral.org. 2. Center for Translational Research in Aging & Longevity, Dept of Health and Kinesiology, Texas A&M University, College Station, TX, USA. 3. Departments of Gastroenterology, Hepatology and Pathobiology, Cleveland Clinic, Cleveland, OH, USA.
Abstract
BACKGROUND & AIMS: Metabolic characterization of a well-defined group of patients could be a powerful tool in revealing metabolic signatures to explain limb muscle weakness in chronic diseases. Studies are currently limited in Chronic Obstructive Pulmonary Disease (COPD) to the identification of differential amino acid concentrations but lack comprehensive analysis of the flux through relevant muscle function related metabolic pathways. METHODS: In 23 stable patients with moderate to very severe COPD and 19 healthy controls, a comprehensive metabolic flux analysis was conducted by administering an intravenous pulse and primed constant infusion of multiple stable tracers of amino acids known to play a role in muscle health. Blood samples were obtained to calculate production (WBP) and interconversion rates, and plasma concentrations of these amino acids. Lower and upper limb muscle strength, muscle mass, lung function, physical activity level, and disease history and characteristics were assessed. RESULTS: The COPD group was characterized by lower and upper limb muscle weakness (P < 0.01) despite preserved muscle mass. Higher values were found in COPD for plasma glutamine, WBP of leucine (P < 0.001), 3-methylhistidine (P < 0.01) (marker of enhanced myofibrillar protein breakdown), citrulline (P < 0.05), and arginine to citrulline conversion (P < 0.05) (reflecting enhanced nitric oxide synthesis). Plasma concentration of β-hydroxy β-methylbutyrate (HMB with anticatabolic, anabolic and contractile properties), WBP of glycine (precursor of creatine and glutathione), and transcutaneous O2 saturation explained up to 79% and 65% of the variation in strength of the lower and upper limb muscles, respectively, in COPD. CONCLUSIONS: Comprehensive metabolic flux analysis revealed a homogenous metabolic signature in stable patients with COPD and a specific metabolic profile in those with skeletal muscle weakness. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No. NCT01787682; URL: www.clinicaltrials.gov.
BACKGROUND & AIMS: Metabolic characterization of a well-defined group of patients could be a powerful tool in revealing metabolic signatures to explain limb muscle weakness in chronic diseases. Studies are currently limited in Chronic Obstructive Pulmonary Disease (COPD) to the identification of differential amino acid concentrations but lack comprehensive analysis of the flux through relevant muscle function related metabolic pathways. METHODS: In 23 stable patients with moderate to very severe COPD and 19 healthy controls, a comprehensive metabolic flux analysis was conducted by administering an intravenous pulse and primed constant infusion of multiple stable tracers of amino acids known to play a role in muscle health. Blood samples were obtained to calculate production (WBP) and interconversion rates, and plasma concentrations of these amino acids. Lower and upper limb muscle strength, muscle mass, lung function, physical activity level, and disease history and characteristics were assessed. RESULTS: The COPD group was characterized by lower and upper limb muscle weakness (P < 0.01) despite preserved muscle mass. Higher values were found in COPD for plasma glutamine, WBP of leucine (P < 0.001), 3-methylhistidine (P < 0.01) (marker of enhanced myofibrillar protein breakdown), citrulline (P < 0.05), and arginine to citrulline conversion (P < 0.05) (reflecting enhanced nitric oxide synthesis). Plasma concentration of β-hydroxy β-methylbutyrate (HMB with anticatabolic, anabolic and contractile properties), WBP of glycine (precursor of creatine and glutathione), and transcutaneous O2 saturation explained up to 79% and 65% of the variation in strength of the lower and upper limb muscles, respectively, in COPD. CONCLUSIONS: Comprehensive metabolic flux analysis revealed a homogenous metabolic signature in stable patients with COPD and a specific metabolic profile in those with skeletal muscle weakness. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No. NCT01787682; URL: www.clinicaltrials.gov.
Authors: Barbora Novotna; Mohammed Abdel-Hamid; Vladimir Koblizek; Michal Svoboda; Karel Hejduk; Vit Rehacek; Josef Bis; Frantisek Salajka Journal: Adv Clin Exp Med Date: 2018-04 Impact factor: 1.727
Authors: Alvise Mason; Mariëlle P K J Engelen; Ivan Ivanov; Gianna M Toffolo; Nicolaas E P Deutz Journal: Am J Physiol Endocrinol Metab Date: 2017-03-07 Impact factor: 4.310
Authors: François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner Journal: Am J Respir Crit Care Med Date: 2014-05-01 Impact factor: 21.405
Authors: B A Van Acker; K W Hulsewé; A J Wagenmakers; N E Deutz; B K Van Kreel; D Halliday; D E Matthews; P B Soeters; M F Von Meyenfeldt Journal: Clin Sci (Lond) Date: 1998-09 Impact factor: 6.124
Authors: Baljit K Ubhi; Kian Kai Cheng; Jiyang Dong; Tobias Janowitz; Duncan Jodrell; Ruth Tal-Singer; William MacNee; David A Lomas; John H Riley; Julian L Griffin; Susan C Connor Journal: Mol Biosyst Date: 2012-10-30
Authors: María D Girón; José D Vílchez; Rafael Salto; Manuel Manzano; Natalia Sevillano; Nefertiti Campos; Josep M Argilés; Ricardo Rueda; José M López-Pedrosa Journal: J Cachexia Sarcopenia Muscle Date: 2015-05-14 Impact factor: 12.910
Authors: Mariëlle P K J Engelen; Renate Jonker; Hooriya Sulaiman; Helena L Fisk; Philip C Calder; Nicolaas E P Deutz Journal: Am J Clin Nutr Date: 2022-09-02 Impact factor: 8.472
Authors: Nicolaas E P Deutz; Pierre Singer; Raven A Wierzchowska-McNew; Marina V Viana; Itai A Ben-David; Olivier Pantet; John J Thaden; Gabriella A M Ten Have; Mariëlle P K J Engelen; Mette M Berger Journal: Clin Nutr Date: 2021-03-18 Impact factor: 7.324
Authors: Clayton L Cruthirds; Nicolaas E P Deutz; Rajesh Harrykissoon; Anthony J Zachria; Mariëlle P K J Engelen Journal: Clin Nutr Date: 2022-03-03 Impact factor: 7.324
Authors: Jaekwan K Park; Nicolaas E P Deutz; Clayton L Cruthirds; Sarah K Kirschner; Hangue Park; Michael L Madigan; Mariëlle P K J Engelen Journal: J Clin Med Date: 2020-02-24 Impact factor: 4.241
Authors: Marisa R Pinson; Nicolaas E P Deutz; Rajesh Harrykissoon; Anthony J Zachria; Mariëlle P K J Engelen Journal: BMC Pulm Med Date: 2021-11-07 Impact factor: 3.317